FGF23 predicts outcomes in heart failure but questions remain unanswered
Authors:
- 19 June 2021
- journal article
- editorial
- Published by Elsevier in International Journal of Cardiology
- Vol. 338, 145-146
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failureInternational Journal of Cardiology, 2018
- 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart FailureJACC, 2017
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureEuropean Heart Journal, 2016
- Elevation of circulating but not myocardial FGF23 in human acute decompensated heart failureNephrology Dialysis Transplantation, 2015
- Fibroblast Growth Factor-23, Cardiovascular Prognosis, and Benefit of Angiotensin-Converting Enzyme Inhibition in Stable Ischemic Heart DiseaseJACC, 2014
- Inorganic phosphate and FGF‐23 predict outcome in stable systolic heart failureEuropean Journal of Clinical Investigation, 2011